Sertraline updated on 07-01-2025

Early intrauterine deaths (< 22 weeks) / Spontaneous abortions

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12955
R49164		 Kitchin, 2022 Miscarriage (pregnancy losses between 4-22 weeks) 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 1.10 [0.72;1.70] 29/103   18,041/72,176 18,070 103
ref
S7522
R22550		 Ozturk (Sertraline), 2016 Miscarriages at least 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 0.48 [0.03;8.38] C 0/17   15/261 15 17
ref
S7874
R23817		 Andersen, 2014 Miscarriage (O021 and O03) early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 1.45 [1.33;1.58] -/4,453   139,210/1,256,956 - 4,453
ref
S8176
R25337		 Nakhai-Pour, 2010 Spontaneous abortions (< 20th week of gestation) during pregnancy (anytime or not specified) nested case control unexposed (general population or NOS) Adjustment: Yes Matched Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.33 [0.85;2.08] 28/-   5,096/- 5,124 -
ref
S7878
R23824		 Yaris, 2005 Spontaneous abortions during pregnancy (anytime or not specified) prospective cohort unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 1.77 [0.21;14.91] C 1/16   9/248 10 16
ref
Total 5 studies 1.43 [1.32;1.55] 23,219 4,589
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kitchin, 2022Kitchin, 2022 1.10[0.72; 1.70]18,0701034%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Ozturk (Sertraline), 2016Ozturk, 2016 1 0.48[0.03; 8.38]15170%ROB confusion: criticalROB selection: unclearROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Andersen, 2014Andersen, 2014 1.45[1.33; 1.58]-4,45393%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Nakhai-Pour, 2010Nakhai-Pour, 2010 1.33[0.85; 2.08]5,124-3%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Yaris, 2005Yaris, 2005 1.77[0.21; 14.91]10160%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (5 studies) I2 = 0% 1.43[1.32; 1.55]23,2194,5890.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Sertraline;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.45[1.33; 1.58]254,4860%NAOzturk (Sertraline), 2016 Andersen, 2014 Yaris, 2005 3 case control studiescase control studies 1.20[0.88; 1.64]23,1941030%NAKitchin, 2022 Nakhai-Pour, 2010 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.43[1.32; 1.55]23,2194,5890%NAKitchin, 2022 Ozturk (Sertraline), 2016 Andersen, 2014 Nakhai-Pour, 2010 Yaris, 2005 5 Tags Adjustment   - No  - No 1.11[0.20; 6.13]25330%NAOzturk (Sertraline), 2016 Yaris, 2005 2   - Yes  - Yes 1.43[1.32; 1.55]23,1944,5560%NAKitchin, 2022 Andersen, 2014 Nakhai-Pour, 2010 3 MatchedMatched 1.33[0.85; 2.08]5,124- -NANakhai-Pour, 2010 1 Monotherapy   - no or not specified  - no or not specified 1.43[1.32; 1.56]18,0954,5890%NAKitchin, 2022 Ozturk (Sertraline), 2016 Andersen, 2014 Yaris, 2005 4   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.33[0.85; 2.08]5,124- -NANakhai-Pour, 2010 1 All studiesAll studies 1.43[1.32; 1.55]23,2194,5890%NAKitchin, 2022 Ozturk (Sertraline), 2016 Andersen, 2014 Nakhai-Pour, 2010 Yaris, 2005 50.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.43.81.7510.000Kitchin, 2022Ozturk (Sertraline), 2016Andersen, 2014Nakhai-Pour, 2010Yaris, 2005

Asymetry test p-value = 0.2115 (by Egger's regression)

slope=0.3923 (0.0347); intercept=-0.5804 (0.3666); t=1.5835; p=0.2115

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.43[1.32; 1.55]162,4204,6080%NAKitchin, 2022 Ozturk (Sertraline), 2016 Andersen, 2014 Nakhai-Pour, 2010 Yaris, 2005 50.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Xing (Spontaneous abortion)Xing (Spontaneous abortion) 1.30[1.04; 1.62]90%-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT2 metaPregmetaPreg 1.43[1.32; 1.55]0%4,589----Kitchin, 2022 Ozturk (Sertraline), 2016 Andersen, 2014 Nakhai-Pour, 2010 Yaris, 2005 50.510.01.0